CPNP-PC Sample Questions & Answers

According to the AAP Red Book and CDC Advisory Committee on Immunization Practices (ACIP) guidelines, high-dose intravenous immunoglobulin (IVIG, 2 g/kg) administered for Kawasaki disease contains circulating maternal/donor antibodies that neutralize live-attenuated parenteral viral vaccines (MMR and varicella), preventing adequate viral replication and protective seroconversion. Therefore, MMR and varicella vaccines must be deferred for 11 months following a 2 g/kg IVIG dose (unless a community measles outbreak warrants earlier vaccination followed by revaccination at >=11 months post-IVIG). Inactivated, toxoid, and conjugate vaccines (such as DTaP and Hib) are not significantly affected by circulating antibody and should be administered on schedule today.

A history of intussusception (regardless of whether it occurred following a previous rotavirus vaccine dose or spontaneously) is an absolute contraindication to the administration of any subsequent doses of rotavirus vaccine (both RV5 and RV1) because postlicensure surveillance demonstrates a small but statistically significant increased risk of intussusception, particularly within 1 to 21 days after the first or second dose. Switching between pentavalent and monovalent formulations is likewise contraindicated. However, the history of intussusception has no bearing on parenteral inactivated/conjugate vaccines, so the second doses of DTaP, IPV, Hib, and PCV should be administered on schedule.

When addressing vaccine hesitancy after an initial presumptive announcement, the PNP should use motivational interviewing principles: validate the parent's desire to protect their child, ask permission to share scientific information, and maintain a strong, unequivocal recommendation focused on cancer prevention (specifically oropharyngeal, anal, penile, and cervical cancers). Immunologically, preadolescents aged 9 to 14 years mount a substantially stronger geometric mean antibody titer response to the 9-valent HPV vaccine than older adolescents and young adults. Because of this robust immune response, immunocompetent patients who initiate the series before their 15th birthday require only a 2-dose schedule (administered at 0 and 6–12 months), whereas initiating the series at age 15 years or older requires a 3-dose schedule (0, 1–2, and 6 months). Furthermore, prophylactic HPV vaccination is most effective when completed well before any sexual contact occurs.

The Bright Futures/AAP Periodicity Schedule explicitly specifies that adolescent hearing screening should be conducted with audiometry that includes high frequencies of 6,000 and 8,000 Hz once between 11 and 14 years, once between 15 and 17 years, and once between 18 and 21 years. Conventional childhood pure-tone screening (500, 1,000, 2,000, and 4,000 Hz) frequently misses early acoustic trauma from personal listening devices, concerts, firearms, or recreational noise, which characteristically manifests as a high-frequency sensorineural notch between 3,000 and 6,000 Hz with recovery or progression at 8,000 Hz.

Homes built before 1978 frequently contain lead-based paint, and dry sanding or scraping generates hazardous respirable lead dust that toddlers ingest via hand-to-mouth activity. Parents should be advised to stop dry sanding immediately, keep the child out of renovation zones, use certified lead-safe contractors and wet-cleaning (HEPA/wet mop) methods, provide a diet adequate in iron, calcium, and vitamin C (which reduce gastrointestinal lead absorption), and complete a 24-month blood lead screening test. Regarding motor vehicle safety, current AAP guidelines state that children should remain in a rear-facing car safety seat as long as possible—until they reach the highest weight or height allowed by their car safety seat's manufacturer—rather than turning forward-facing simply upon turning 2 years old.

Per the Bright Futures/AAP Recommendations for Preventive Pediatric Health Care, when substance or opioid use is identified as a concern via the CRAFFT screening tool, clinicians should conduct brief motivational interviewing, counsel on the high lethal risk of illicitly manufactured fentanyl in counterfeit pressed pills, and recommend or prescribe naloxone for overdose reversal. Simultaneously, sexually active adolescents should receive confidential STI and HIV screening (with universal HIV screening recommended at least once between ages 15 and 21 and at least annually for high-risk youth) and counseling on HIV pre-exposure and post-exposure prophylaxis (PrEP/PEP), while safeguarding adolescent privacy in the electronic health record under the 21st Century Cures Act privacy exceptions.